Bjørn-Eivind Seljelid Bordewick Kirsebom

• Gonzalez-Ortiz, Fernando; Kirsebom, Bjørn-Eivind Seljelid; Contador, José; Tanley, Jordan E.; Selnes, Per & Gísladóttir, Berglind [Vis alle 33 forfattere av denne artikkelen] (2024). Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Nature Communications. ISSN 2041-1723. 15(1). doi: 10.1038/s41467-024-47286-5.
• Mehdipour Ghazi, Mostafa; Selnes, Per; Timón-Reina, Santiago; Tecelão, Sandra; Ingala, Silvia & Bjørnerud, Atle [Vis alle 9 forfattere av denne artikkelen] (2024). Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts. Frontiers in Aging Neuroscience. ISSN 1663-4365. 16. doi: 10.3389/fnagi.2024.1345417.
• Hemminghyth, Mathilde Suhr; Chwiszczuk, Luiza; Breitve, Monica Haraldseid; Gisladottir, Berglind; Grøntvedt, Gøril Rolfseng & Nakling, Arne Exner [Vis alle 9 forfattere av denne artikkelen] (2023). Cerebrospinal fluid neurofilament light chain mediates age-associated lower learning and memory in healthy adults. Neurobiology of Aging. ISSN 0197-4580. 135, s. 39–47. doi: 10.1016/j.neurobiolaging.2023.12.005. Fulltekst i vitenarkiv
• Nordengen, Kaja; Kirsebom, Bjørn-Eivind Seljelid; Richter, Grit; Pålhaugen, Lene; Gisladottir, Berglind & Siafarikas, Nikias Ioannis [Vis alle 22 forfattere av denne artikkelen] (2023). Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease. Journal of Neuroinflammation. ISSN 1742-2094. 20(1). doi: 10.1186/s12974-023-02973-w. Fulltekst i vitenarkiv
• Aspli, Klaus Thanke; Aaseth, Jan; Holmøy, Trygve; Blennow, Kaj; Zetterberg, Henrik & Kirsebom, Bjørn-Eivind Seljelid [Vis alle 8 forfattere av denne artikkelen] (2023). CSF, Blood, and MRI Biomarkers in Skogholt’s Disease—A Rare Neurodegenerative Disease in a Norwegian Kindred. Brain Sciences. ISSN 2076-3425. 13(11). doi: 10.3390/brainsci13111511. Fulltekst i vitenarkiv
• Espenes, Johan Jacob; Lorentzen, Ingrid Myrvoll; Eliassen, Ingvild Vøllo; Hessen, Erik; Waterloo, Knut K & Timón, Santiago [Vis alle 10 forfattere av denne artikkelen] (2023). Regression-based normative data for the D-KEFS Color-Word Interference Test in Norwegian adults ages 20–85. The Clinical Neuropsychologist. ISSN 1385-4046. doi: 10.1080/13854046.2023.2276967. Fulltekst i vitenarkiv
• Öhman, Fredrik; Eckerström, Marie; Hessen, Erik; Espenes, Johan Jacob; Eliassen, Ingvild Vøllo & Lorentzen, Ingrid Myrvoll [Vis alle 12 forfattere av denne artikkelen] (2023). Demographically adjusted Rey–Osterrieth Complex Figure Test norms in a Swedish and Norwegian cohort aged 49–77 years and comparison with North American norms. Scandinavian Journal of Psychology. ISSN 0036-5564. doi: 10.1111/sjop.12966. Fulltekst i vitenarkiv
• Timón, Santiago; Rincón, Mariano; Martínez-Tomás, Rafael; Kirsebom, Bjørn-Eivind Seljelid & Fladby, Tormod (2023). A Knowledge Graph Framework for Dementia Research Data. Applied Sciences. ISSN 2076-3417. 13(18), s. 1–23. doi: 10.3390/app131810497. Fulltekst i vitenarkiv
• Lorentzen, Ingrid Myrvoll; Espenes, Johan Jacob; Eliassen, Ingvild Vøllo; Hessen, Erik; Waterloo, Knut K & Nakling, Arne Exner [Vis alle 10 forfattere av denne artikkelen] (2023). Investigating the relationship between allocentric spatial working memory and biomarker status in preclinical and prodromal Alzheimer’s disease. Applied neuropsychology: Adult. ISSN 2327-9095. doi: 10.1080/23279095.2023.2236262. Fulltekst i vitenarkiv
• Jarholm, Jonas Alexander; Bjørnerud, Atle; Dalaker, Turi Olene; Sadat Akhavi, Mehdi; Kirsebom, Bjørn-Eivind & Pålhaugen, Lene [Vis alle 14 forfattere av denne artikkelen] (2023). Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort. Journal of Alzheimer's Disease. ISSN 1387-2877. 94(1), s. 259–279. doi: 10.3233/JAD-221274. Fulltekst i vitenarkiv
• Waggestad, Therese Händel; Kirsebom, Bjørn-Eivind; Strobel, Carsten; Wallin, Anders; Eckerström, Marie & Fladby, Tormod [Vis alle 7 forfattere av denne artikkelen] (2023). Improving validity of the trail making test with alphabet support. Frontiers in Psychology. ISSN 1664-1078. 14. doi: 10.3389/fpsyg.2023.1227578. Fulltekst i vitenarkiv Vis sammendrag

  Objective: The Trail Making Test (TMT) is commonly used worldwide to evaluate cognitive decline and car driving ability. However, it has received critique for its dependence on the Latin alphabet and thus, the risk of misclassifying some participants. Alphabet support potentially increases test validity by avoiding misclassification of executive dysfunction in participants with dyslexia and those with insufficient automatization of the Latin alphabet. However, Alphabet support might render the test less sensitive to set-shifting, thus compromising the validity of the test. This study compares two versions of the TMT: with and without alphabet support. Methods: We compared the TMT-A, TMT-B, and TMT-B:A ratios in two independent normative samples with (n = 220) and without (n = 64) alphabet support using multiple regression analysis adjusted for age and education. The sample comprised Scandinavians aged 70–84 years. Alphabet support was included by adding the Latin alphabet A–L on top of the page on the TMT-B. We hypothesized that alphabet support would not change the TMT-B:A ratio. Results: After adjusting for age and years of education, there were no significant differences between the two samples in the TMT-A, TMT-B, or the ratio score (TMT-B:A). Conclusion: Our results suggest that the inclusion of alphabet support does not alter TMT’s ability to measure set-shifting in a sample of older Scandinavian adults.

• Kirsebom, Bjørn-Eivind; Richter, Grit; Nordengen, Kaja; Aarsland, Dag; Bråthen, Geir & Tijms, Betty M [Vis alle 15 forfattere av denne artikkelen] (2022). Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients. Brain Communications. ISSN 2632-1297. 4(5), s. 1–16. doi: 10.1093/braincomms/fcac244. Fulltekst i vitenarkiv Vis sammendrag

  Cerebrospinal fluid (CSF) β-site amyloid precursor protein cleaving enzyme 1 (BACE1), neurogranin and the neurogranin/BACE1 ratio are proposed markers for Alzheimer’s disease. BACE1 is also a drug target. However, CSF levels may differ between early-stage amyloid plaque formation (A) and later stage downstream tau-tangle pathology (T) and neurodegeneration (N) and may be expressed as an A/T/N stage (e.g. A+/T−/N or A+/T+/N+). Whether BACE1 and neurogranin levels are persistent traits or change with disease progression is unknown. The aim of this study was to investigate whether CSF neurogranin and BACE1 concentrations differ between A/T/N stages, whether these change over time and correlate with memory decline. This may have implications for patient selection in future trials. We used CSF markers to determine A/T/N stage using amyloid beta42/40 ratio, p-tau181 and total-tau respectively in predementia Alzheimer’s disease cases (n = 176) [including cases that progressed to dementia (n = 10)] and controls (n = 74) from the Norwegian Dementia Disease Initiation cohort. We selected cases at the presumed early (A+/T−/N−, n = 86) and late stages (A+/T+/N+, n = 90) of the Alzheimer’s disease continuum and controlled with normal markers (A−/T−/N−, n = 74). A subset of subjects in all A/T/N groups underwent repeat CSF sampling at approximately 2-year intervals up to 6 years from baseline. Using linear mixed models, longitudinal measurements of CSF BACE1 and neurogranin levels in A+/T−/N− and A+/T+/N+ as compared to A−/T−/N− healthy controls were performed. Next, we measured changes in CSF BACE1 and neurogranin levels in cases that progressed from A−/T−/N− to A+/T−/N− (n = 12), from A+/T−/N− to A+/T or N+ (n = 12), remained stable A+/T−/N− (n = 26), remained stable A+/T+/N+ (n = 28) compared with controls remaining stable A−/T−/N− (n = 33). Lastly, associations between these markers and memory decline were assessed. Compared with A−/T−/N− healthy controls, neurogranin was unaltered in A+/T−/N− (n.s.) but higher in A+/T+/N+ (P < 0.0001). In contrast, BACE1 was lower in A+/T−/N− (P < 0.05) and higher in A+/T+/N+ (P < 0.0001). The neurogranin/BACE1 ratio was increased in both A+/T−/N− (P < 0.05) and A+/T+/N+ (P < 0.0001) groups as compared to A-/T-/N- healthy controls and was more strongly associated with memory decline (b = −0.29, P = 0.0006) than neurogranin (b = −0.20, P = 0.002) and BACE1 (b = −0.13, P = 0.046). Neurogranin and BACE1 level differences remained stable over time not only within A/T/N groups but also in patients progressing to more pathological A/T/N stages (e.g. progressing from A+/T−/N− to A + T or N+) and in cases progressing to dementia. Our results suggest that neurogranin and BACE1 levels may differentiate pathomechanistic Alzheimer’s disease subgroups, putatively with different options for treatment.

• Eliassen, Ingvild Vøllo; Kirsebom, Bjørn-Eivind; Fladby, Tormod; Waterloo, Knut; Sando, Sigrid Botne & Hemminghyth, Mathilde Suhr [Vis alle 12 forfattere av denne artikkelen] (2022). Regression-Based Cognitive Change Norms Applied in Biochemically Defined Predementia Alzheimer’s Disease. Neuropsychology. ISSN 0894-4105. 37(1), s. 32–43. doi: 10.1037/neu0000853. Fulltekst i vitenarkiv Vis sammendrag

  Objective: We aim to develop 2-year cognitive change norms for adults ages 41–84 for six cognitive tests, and to evaluate these norms in groups with AD biomarkers. Background: Practice effects are common in repeated neuropsychological testing. Not accounting for practice effects may obscure cognitive decline in early Alzheimer’s disease (AD). Method: We developed standardized regression-based change norms from normative samples consisting of healthy controls from the Dementia Disease Initiation study (n = 125), the Trønderbrain study (n = 57), and the Gothenburg mild cognitive impairment (MCI) study (n = 65). Norms were applied in a sample with cognitive symptoms (subjective cognitive decline or MCI) and AD cerebrospinal fluid (CSF) biomarkers (n = 246), classified according to the A/T/N system. Results: The change norms adjusted for pertinent demographics and practice effects. The group with cognitive complaints displayed a trend toward cognitive decline compared to the normative group, with the A+T/N+ subgroup showing the most marked decline. This was observed in tests of episodic memory and cognitive flexibility/divided attention. Conclusions: We present 2-year cognitive change norms for adults between 41 and 84 years, adjusted for practice and demographics. A web-based change norm calculator is provided.

• Espenes, Jacob; Eliassen, Ingvild Vøllo; Öhman, Fredrik; Hessen, Erik; Waterloo, Knut K & Eckerström, Marie [Vis alle 13 forfattere av denne artikkelen] (2022). Regression‐based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49–79 and comparison with published norms. The Clinical Neuropsychologist. ISSN 1385-4046. doi: 10.1080/13854046.2022.2106890. Fulltekst i vitenarkiv
• Borda, Miguel Germán; Ferreira, Daniel; Selnes, Per; Tovar-Rios, Diego Alejandro; Jaramillo-Jiménez, Alberto & Kirsebom, Bjørn-Eivind [Vis alle 12 forfattere av denne artikkelen] (2022). Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness. Dementia and Geriatric Cognitive Disorders. ISSN 1420-8008. 51(1), s. 63–72. doi: 10.1159/000522094. Fulltekst i vitenarkiv
• Siafarikas, Nikias Ioannis; Kirsebom, Bjørn-Eivind; Srivastava, Deepak P; Eriksson, Cecilia Magdalena; Auning, Eirik & Hessen, Erik [Vis alle 10 forfattere av denne artikkelen] (2021). Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. Scientific Reports. ISSN 2045-2322. 11. doi: 10.1038/s41598-021-99794-9. Fulltekst i vitenarkiv Vis sammendrag

  To explore markers for synaptic function and Alzheimer disease (AD) pathology in late life depression (LLD), predementia AD and normal controls (NC). A cross-sectional study to compare cerebrospinal fluid (CSF) levels of neurogranin (Ng), Beta-site amyloid-precursor-protein cleaving enzyme1 (BACE1), Ng/BACE1 ratio and Amyloid-β 42/40 ratio, phosphorylated-tau and total-tau in LLD with (LLD AD) or without (LLD NoAD) AD pathology, predementia AD and normal controls (NC). We included 145 participants (NC = 41; predementia AD = 66 and LLD = 38). LLD comprised LLD AD (n = 16), LLD NoAD (n = 19), LLD with non-AD typical changes (n = 3, excluded). LLD AD (pADJ < 0.05) and predementia AD (pADJ < 0.0001) showed significantly higher Ng than NC. BACE1 and Ng/BACE1 ratio were altered similarly. Compared to LLD NoAD, LLD AD showed significantly higher Ng (pADJ < 0.001), BACE1 (pADJ < 0.05) and Ng/BACE1 ratio (pADJ < 0.01). All groups had significantly lower Aβ 42/40 ratio than NC (predementia AD and LLD AD, p < 0.0001; LLD NoAD, p < 0.05). Both LLD groups performed similarly on tests of memory and executive function, but significantly poorer than NC. Synaptic function in LLD depended on AD pathology. LLD showed an association to Amyloid dysmetabolism. The LLD groups performed poorer cognitively than NC. LLD AD may be conceptualized as “predementia AD with depression”.

• Lorentzen, Ingrid Myrvoll; Espenes, Johan Jacob; Hessen, Erik; Waterloo, Knut; Bråthen, Geir & Timón, Santiago [Vis alle 9 forfattere av denne artikkelen] (2021). Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample. Applied neuropsychology: Adult. ISSN 2327-9095. doi: 10.1080/23279095.2021.1918128. Fulltekst i vitenarkiv Vis sammendrag

  The FAS phonemic fluency test is a commonly used neuropsychological test of executive function and processing speed. Although Norwegian discrete norms have been developed for the FAS test, American regression-based norms are frequently used by clinicians in Norway. However, language and cultural differences impact performance on the FAS test, and using foreign norms may not be appropriate. Moreover, while discrete norming relies on stratified subgroups of demographics, regression-based norming uses the entire sample to estimate the influence of demographics on performance and may thus improve normative estimates. Here we develop regression-based norms for the FAS phonemic fluency test based on n = 204 healthy Norwegian controls between the ages 40−84 from the Norwegian Dementia Disease Initiation cohort (DDI). We compare the proposed regression norms to published Norwegian discrete norms and American regression-based norms in an independent sample of n = 182 cognitively healthy adults reporting subjective cognitive decline (SCD). We found that years of education was the only significant predictor of FAS performance in our normative sample, accounting for 14.9% of the variance. Both the proposed regression-based norms and previously published discrete norms adequately adjusted for demographics in the independent sample. In contrast, the American norms underestimated the effect of education and overestimated the effect of age. While both the proposed Norwegian regression norms and the previously published discrete norms are suitable for use in Norway, the proposed regression norms may be less vulnerable to sub-stratification sample characteristics posed by discrete norming procedures, and thereby improve normative estimation.

• Eliassen, Ingvild Vøllo; Fladby, Tormod; Kirsebom, Bjørn-Eivind; Waterloo, Knut; Eckerström, Marie & Wallin, Anders [Vis alle 9 forfattere av denne artikkelen] (2020). Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia. Neuropsychology. ISSN 0894-4105. 34(8), s. 851–861. doi: 10.1037/neu0000698. Fulltekst i vitenarkiv Vis sammendrag

  Objective: To assess the role of brief neuropsychological assessments in prediction and identification of Alzheimer’s disease (AD) pathology and progression to AD dementia. Method: Adults (N = 255; range = 40–81 years) with self-reported cognitive decline underwent baseline and 2-year follow-up clinical assessment, including a brief neuropsychological screening and lumbar puncture. Five different mild cognitive impairment (MCI) algorithms were applied on baseline cognitive test results: one conventional, three amnestic (lenient, stringent, multidomain), and one comprehensive criterion. We compared predictive and diagnostic accuracy of these MCI criteria by performing logistic regression analyses and calculating diagnostic accuracy measures for 2-year outcomes of (1) clinical diagnosis of AD dementia and (2) cerebrospinal fluid biomarkers in the Alzheimer’s continuum. Results: The lenient amnestic MCI criterion showed the largest effect size for predicting progression to AD dementia (OR = 13.762, 99% CI = 1.969–96.194, p = .001) and AD biomarkers (OR = 4.855, 99% CI = 1.974–11.924, p < .001) after 2 years. This criterion was sensitive for progression to dementia (sensitivity = 92.0%, specificity = 54.8%, positive likelihood ratio [LR+] = 2.03, LR− = 0.15) and showed the highest overall diagnostic accuracy for AD biomarkers (sensitivity = 72.7%, specificity = 59.1%, LR+ = 1.78, negative likelihood ratio [LR−] = 0.46). The multidomain amnestic MCI criterion produced the highest specificity for dementia (sensitivity = 76.0%, specificity = 73.0%, LR+ = 2.82, LR− = 0.33) and AD biomarkers (sensitivity = 46.8% specificity = 70.9% LR+ = 1.61, LR− = 0.75). Conclusions: Defining MCI using a brief neuropsychological battery provided limited accuracy for progression to AD dementia and cerebrospinal fluid Aβ. The lenient amnestic MCI criterion identified the highest number of individuals who progressed to clinical AD or showed biomarker pathology, but this approach included a substantial number of false positives. (PsycInfo Database Record (c) 2020 APA, all rights reserved)

• Espenes, Johan Jacob; Hessen, Erik; Eliassen, Ingvild Vøllo; Waterloo, Knut; Eckerström, Marie & Sando, Sigrid Botne [Vis alle 10 forfattere av denne artikkelen] (2020). Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years. The Clinical Neuropsychologist. ISSN 1385-4046. 34, s. 1–18. doi: 10.1080/13854046.2020.1829068. Fulltekst i vitenarkiv Vis sammendrag

  Objective: The trail making test (TMT) is one of the most widely used neuropsychological tests. TMT-A provides measures of visual scanning/visuomotor speed and TMT-B involves additional demands on executive functions. Derived scores TMT B-A and TMT B/A enhance measures of executive functioning. However, simple B-A subtraction may lead to false estimates of executive dysfunction in clinical samples. Norms for TMT have been published in several countries but are currently lacking for Scandinavia. Methods: A total of 292 healthy controls between age 41 and 84 years were included from the Norwegian “Dementia Disease Initiation” (DDI) study (n ¼ 170) and the Gothenburg Mild Cognitive Impairment (MCI) study (n ¼ 122). We used a regression-based procedure to develop demographically adjusted norms for basic (TMT-A and TMT-B) and derived measures (TMT B-A and B/A). We also propose a regression-based alternative to the TMT B-A measure named “TMT-b”. The proposed norms were compared to norms from Heaton et al. and Tombaugh. Results: Due to differences in the estimated normative effects of demographics on performance, the proposed norms for TMT were better suited in the Scandinavian sample compared with published non-Scandinavian norms. The proposed TMT-b measure was highly correlated to TMT B-A (r ¼ 0.969, p < 0.001). Conclusion: We here propose demographically adjusted norms for the TMT for ages 41 through 84 years based on a Scandinavian

• Bergland, Anne Katrine; Proitsi, Petroula; Kirsebom, Bjørn-Eivind; Sønnesyn, Hogne; Hye, Abdul & Larsen, Alf Inge [Vis alle 11 forfattere av denne artikkelen] (2020). Exploration of plasma lipids in mild cognitive impairment due to Alzheimer's disease . Journal of Alzheimer's Disease. ISSN 1387-2877. 77(3), s. 1117–1127. doi: 10.3233/JAD-200441.
• Espenes, Ragna; Kirsebom, Bjørn-Eivind; Eriksson, Cecilia Magdalena; Waterloo, Knut K; Hessen, Erik & Johnsen, Stein Harald [Vis alle 8 forfattere av denne artikkelen] (2020). Amyloid plaques and symptoms of depression links to medical help-seeking due to subjective cognitive decline. Journal of Alzheimer's Disease. ISSN 1387-2877. 75(3), s. 879–890. doi: 10.3233/JAD-190712. Fulltekst i vitenarkiv
• Hessen, Erik; Kirsebom, Bjørn-Eivind; Eriksson, Cecilia Magdalena; Eliassen, Carl Fredrik Andestad; Nakling, Arne & Bråthen, Geir [Vis alle 9 forfattere av denne artikkelen] (2019). In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. Journal of Alzheimer's Disease. ISSN 1387-2877. 67(2), s. 715–723. doi: 10.3233/JAD-180964. Fulltekst i vitenarkiv
• Nordengen, Kaja; Kirsebom, Bjørn-Eivind; Henjum, Kristi; Selnes, Per; Gisladottir, Berglind & Wettergreen, Marianne [Vis alle 12 forfattere av denne artikkelen] (2019). Glial activation and inflammation along the Alzheimer's disease continuum. Journal of Neuroinflammation. ISSN 1742-2094. 16:46, s. 1–13. doi: 10.1186/s12974-019-1399-2. Fulltekst i vitenarkiv
• Kirsebom, Bjørn-Eivind; Espenes, Ragna; Hessen, Erik; Waterloo, Knut; Johnsen, Stein Harald & Gundersen, Elisabeth [Vis alle 10 forfattere av denne artikkelen] (2019). Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years. The Clinical Neuropsychologist. ISSN 1385-4046. 33, s. 27–39. doi: 10.1080/13854046.2019.1574902. Fulltekst i vitenarkiv
• Kirsebom, Bjørn-Eivind; Nordengen, Kaja; Selnes, Per; Waterloo, Knut; Torsetnes, Silje Bøen & Gisladottir, Berglind [Vis alle 12 forfattere av denne artikkelen] (2018). Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. ISSN 2352-8737. 4, s. 617–627. doi: 10.1016/j.trci.2018.10.003. Fulltekst i vitenarkiv
• Fladby, Tormod; Pålhaugen, Lene; Selnes, Per; Waterloo, Knut; Bråthen, Geir & Hessen, Erik [Vis alle 27 forfattere av denne artikkelen] (2017). Detecting at-risk Alzheimer's disease cases. Journal of Alzheimer's Disease. ISSN 1387-2877. 60(1), s. 97–105. doi: 10.3233/JAD-170231.
• Kirsebom, Bjørn-Eivind Seljelid Bordewic; Espenes, Ragna; Waterloo, Knut; Hessen, Erik; Johnsen, Stein Harald & Bråthen, Geir [Vis alle 8 forfattere av denne artikkelen] (2017). Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients. Journal of Alzheimer's Disease. ISSN 1387-2877. 60(4), s. 1621–1631. doi: 10.3233/JAD-170385. Fulltekst i vitenarkiv

Se alle arbeider i Cristin

• Hemminghyth, Mathilde Suhr; Breitve, Monica Haraldseid; Gisladottir, Berglind; Grøntvedt, Gøril Rolfseng; Nakling, Arne Exner & Fladby, Tormod [Vis alle 8 forfattere av denne artikkelen] (2023). Cerebrospinal fluid neurofilament light chain mediates age-related decline in learning and memory in healthy adults.
• Chwiszczuk, Luiza; Breitve, Monica Haraldseid; Kirsebom, Bjørn-Eivind; Selnes, Per; Fløvig, John Christian Jøraholmen & Knapskog, Anne Brita [Vis alle 10 forfattere av denne artikkelen] (2023). The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. Frontiers in Aging Neuroscience. ISSN 1663-4365. 15. doi: 10.3389/fnagi.2023.1163184. Fulltekst i vitenarkiv
• Siafarikas, Nikias Ioannis; Kirsebom, Bjørn-Eivind; Srivastava, Deepak P.; Eriksson, Cecilia Magdalena; Auning, Eirik & Hessen, Erik [Vis alle 10 forfattere av denne artikkelen] (2022). Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression (Scientific Reports, (2021), 11, 1, (20375), 10.1038/s41598-021-99794-9). Scientific Reports. ISSN 2045-2322. 12(1). doi: 10.1038/s41598-022-22274-1.
• Espenes, Johan Jacob; Eliassen, Ingvild Vøllo; Fladby, Tormod; Eckerström, Marie; Anders, Wallin & Waterloo, Knut [Vis alle 8 forfattere av denne artikkelen] (2020). Demographically adjusted test norms for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults from 41 to 79 years.
• Kirsebom, Bjørn-Eivind (2020). Hva vet vi om Alzheimers sykdom i dag, og finnes det en kur? Nordlys. ISSN 0805-5440.
• Eliassen, Ingvild Vøllo; Kirsebom, Bjørn-Eivind; Hessen, Erik; Selnes, Per; Waterloo, Knut & Fladby, Tormod (2019). Distractor List Errors from Verbal Learning Test May Reveal Deficient Temporal Memory Encoding in Predementia Alzheimer’s Disease .
• Kirsebom, Bjørn-Eivind (2019). Tromsø-forskere jobber intenst med å løse alzheimer-gåten. [Avis]. iTromsø.
• Kirsebom, Bjørn-Eivind (2019). Vil avdekke Alzheimers sykdom så tidlig som mulig. [Internett]. Psykologisk.no.
• Kirsebom, Bjørn-Eivind (2019). Frykter fordobling av demenstilfeller innen 2050: Tromsø-forskere undersøker om blåbær kan være kuren. [Avis]. iTromsø.
• Kirsebom, Bjørn-Eivind & Buberg, Tine Viktoria (2019). Forsker på demens: – Antioksidanter fra blåbær kan bidra til å bremse demens. [Avis]. Indre Akershus blad.
• Kirsebom, Bjørn-Eivind; Selnes, Per; Richter, Grit; Gisladottir, Berglind; Wettergreen, Marianne & Torsetnes, Silje Bøen [Vis alle 9 forfattere av denne artikkelen] (2019). Cerebrospinal fluid Neurogranin/BACE1 ratio differentiate normal controls, pre-dementia Alzheimer’s and Parkinson’s disease cases.
• Espenes, Johan Jacob; Kirsebom, Bjørn-Eivind; Eliassen Vøllo, Ingvild; Espenes, Ragna; Waterloo, Knut & Hessen, Erik [Vis alle 7 forfattere av denne artikkelen] (2019). Demographically adjusted norms for basic and derived measures on the Trail Making Test A & B based on a Norwegian sample age 40 – 84 years.
• Richter, Grit; Kirsebom, Bjørn-Eivind; Selnes, Per; Nordengen, Kaja; Waterloo, Knut & Gisladottir, Berglind [Vis alle 12 forfattere av denne artikkelen] (2019). An amyloid-coupled pre-dementia increased CSF neurogranin/BACE1 ratio may reflect early synapse affection in APOE-ɛ4 homozygotes.
• Espenes, Ragna; Kirsebom, Bjørn-Eivind; Eriksson, Cecilia Magdalena; Waterloo, Knut; Johnsen, Stein Harald & Hessen, Erik [Vis alle 7 forfattere av denne artikkelen] (2019). Medical help-seeking in Subjective Cognitive Decline associated with lower CSF Aβ1-42 and reduced memory performance.
• Richter, Grit; Kirsebom, Bjørn-Eivind; Selnes, Per; Nordengen, Kaja; Waterloo, Knut & Gisladottir, Berglind [Vis alle 12 forfattere av denne artikkelen] (2019). Early increase in CSF neurogranin/BACE1 ratio in predementia APOE-ɛ4 homozygote cases with amyloid pathology .
• Kirsebom, Bjørn-Eivind; Nordengen, Kaja; Selnes, Per; Waterloo, Knut; Brix, Britta & Vanmechelen, Eugeen [Vis alle 8 forfattere av denne artikkelen] (2018). INCREASED CSF NEUROGRANIN/BACE1 RATIO IN AMYLOID POSITIVE SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE.
• Kirsebom, Bjørn-Eivind; Espenes, Ragna; Waterloo, Knut; Johnsen, Stein Harald & Fladby, Tormod (2017). Screening for Alzheimer's Disease: Cognitive Impairent in Self-Referred and Memory Clinic-Referred Patients.

Se alle arbeider i Cristin